White Hope Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.30 M
as on 05-07-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2842.17%
(FY 2021)
- Profit 255.37%
(FY 2021)
- Ebitda 777.62%
(FY 2021)
- Net Worth 54.54%
(FY 2021)
- Total Assets 621.72%
(FY 2021)
About White Hope Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Siddharth Lunkad, Harshvardhan Lunkad, Abeer Lunkad, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233MH2015PTC265308
- Company No.
265308
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at White Hope Pharmaceutical?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siddharth Lunkad  | Director | 08-Jun-2015 | Current |
| Harshvardhan Lunkad | Director | 08-Jun-2015 | Current |
| Abeer Lunkad | Director | 08-Jun-2015 | Current |
| Aayan Lunkad | Director | 08-Jun-2015 | Current |
| Manoj Jain | Director | 08-Jun-2015 | Current |
Financial Performance and Corporate Structure Insights of White Hope Pharmaceutical.
White Hope Pharmaceutical Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 2842.17% increase. The company also saw a substantial improvement in profitability, with a 255.37% increase in profit. The company's net worth Soared by an impressive increase of 54.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of White Hope Pharmaceutical?
In 2021, White Hope Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Prasil Industries Private LimitedInactive For E-Filing 4 months 2 days
Abeer Lunkad and Aayan Lunkad are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at White Hope Pharmaceutical?
Unlock and access historical data on people associated with White Hope Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of White Hope Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped White Hope Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
